157 related articles for article (PubMed ID: 33469107)
1. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600
Klein S; Mauch C; Brinker K; Noh KW; Knez S; Büttner R; Quaas A; Helbig D
Sci Rep; 2021 Jan; 11(1):1834. PubMed ID: 33469107
[TBL] [Abstract][Full Text] [Related]
2. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
3. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract][Full Text] [Related]
4. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
Haugh A; Daud AI
Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
7. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
10.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
11. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
[TBL] [Abstract][Full Text] [Related]
13. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
14. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens.
Lee PJ; Dennis K; Madan R; Fan F
Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186
[TBL] [Abstract][Full Text] [Related]
17. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas.
Wang HY; Wu XY; Zhang X; Yang XH; Long YK; Feng YF; Wang F
Oncologist; 2020 Feb; 25(2):e291-e301. PubMed ID: 32043781
[TBL] [Abstract][Full Text] [Related]
19. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Plesca I; Tunger A; Müller L; Wehner R; Lai X; Grimm MO; Rutella S; Bachmann M; Schmitz M
Front Immunol; 2020; 11():364. PubMed ID: 32194568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
